Compare Cassava Sciences Inc (FLNA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PepsiCo, Inc. — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while PepsiCo, Inc. trades at $137.92 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 3956.2× Cassava Sciences Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PEP | |
|---|---|---|
Market Cap | $47.75M | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $170.44 |
52-Week Low | $0.87 | $134.95 |
Enterprise Value | -$34.93M | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
PepsiCo (PEP) trades at $138.11, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78%, and has beaten EPS estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts expect in-line Q1 2026 results.
The stock offers a solid dividend yield and trades below the consensus price target of $158.79, suggesting upside potential. Risks include competitive pressures and sensitivity to consumer spending trends, but strong cash flow and institutional buying support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
